Business
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
RAHWAY, N.J., March 17, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it will present new clinical and real-world data reaffirming the long-term effectiveness of the company’s 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and its 4-valent HPV vaccine, GARDASIL® (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases at the EUROGIN Internati
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/259f8821287938f1f63a15769228b35c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L4Z5c8FNCE22xn5TITo2BA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/259f8821287938f1f63a15769228b35c","width":480,"height":217}},"lazy":false},{"type":"text","content":"Data show long-term effectiveness of GARDASIL®9 and GARDASIL® 14 years and 18 years, respectively, following vaccination with 3 doses","length":133,"tagName":"p","attribs":{}},{"type":"text","content":"Data on certain HPV-related oropharyngeal cancers reinforce the importance of vaccination for both females and males","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., March 17, 2026--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it will present new clinical and real-world data reaffirming the long-term effectiveness of the company’s 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and its 4-valent HPV vaccine, GARDASIL® (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna, Austria, from March 18-21.","length":595,"tagName":"p"},{"type":"text","content":"Data to be presented include results from studies evaluating the long-term effectiveness of HPV vaccination in women 16 to 26 years of age, showing vaccine effectiveness for at least 14 years following 3 doses of the 9-valent vaccine, and vaccine effectiveness up to 18 years after 3 doses of the quadrivalent vaccine against HPV 16/18-related high-grade cervical disease.","length":372,"tagName":"p"},{"type":"text","content":"The company will share additional data on certain HPV-related oropharyngeal cancers, and adult- and juvenile-onset Recurrent Respiratory Papillomatosis (RRP) through studies done in the U.S., Denmark, Sweden, and the United Kingdom.","length":232,"tagName":"p"},{"type":"text","content":""Nearly two decades after the U.S. FDA approval of GARDASIL in June 2006, we are proud to present these d...